CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.
about
CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritisCD40 in coronary artery disease: a matter of macrophages?The signaling role of CD40 ligand in platelet biology and in platelet component transfusionProperdin: a tightly regulated critical inflammatory modulatorPlatelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.Bidirectional crosstalk between platelets and monocytes initiated by Toll-like receptor: an important step in the early defense against fungal infections?CD40L and Its Receptors in Atherothrombosis-An UpdateCD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injuryCD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells.Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk.Soluble CD40 ligand stimulates CD40-dependent activation of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burstRoles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury.Crucial role of CD40 signaling in vascular wall cells in neointimal formation and vascular remodeling after vascular interventionsPlatelet PI3Kγ Contributes to Carotid Intima-Media Thickening under Severely Reduced Flow Conditions.Higher levels of circulating monocyte-platelet aggregates are correlated with viremia and increased sCD163 levels in HIV-1 infection.The anti-inflammatory effects of exercise training promote atherosclerotic plaque stabilization in apolipoprotein E knockout mice with diabetic atherosclerosis.CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammationNew strategy for sepsis: Targeting a key role of platelet-neutrophil interaction.Platelets influence vascularized organ transplants from start to finishPlatelets: essential components of the immune system.Early growth response protein 1 promotes restenosis by upregulating intercellular adhesion molecule-1 in vein graft.Mediation of transitional B cell maturation in the absence of functional Bruton's tyrosine kinase.Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype.CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial.Effect of a fatty meal on inflammatory markers in healthy volunteers with a family history of type 2 diabetes.TNF and CD28 Signaling Play Unique but Complementary Roles in the Systemic Recruitment of Innate Immune Cells after Staphylococcus aureus Enterotoxin A Inhalation.The effect of trans-resveratrol on platelet-neutrophil complex formation and neutrophil burst in hypercholesterolemic rats.New frontiers for platelet CD154.Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis.Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.CD154 Induces Matrix Metalloproteinase-9 Secretion in Human Podocytes.CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction.Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo.
P2860
Q21285053-51C3AA4F-2FF6-4405-85E9-B9ADF5208185Q26752784-598FBDE5-0DF5-462B-8719-7C40F12631CBQ26863134-640EE63F-84E4-4AE1-A43B-C2C87801C256Q28069187-5309F22E-96B3-4891-B1BF-724D6323A4E8Q30497499-5C457A44-F742-4EF6-BF46-0F88681FC3A0Q33401507-378271F5-AEDF-4850-8C8B-F99BD9E07705Q33814059-08054815-6CFC-4AB8-ADD4-6C531DE8B972Q34005419-2D5A29AD-3589-4C48-AA81-CD23E220B08FQ34336527-6F45A637-85F9-490A-9F76-57424D730776Q34549341-F570A5A0-3190-4721-8C3B-51290696CAA5Q34778615-741E5B76-4BFB-4C2E-ABCD-A3DF7E13854EQ35210912-10FAE8A8-38A8-4DE5-9C7A-AA02F0244036Q35621648-9C9FA27D-1C14-49C4-B52E-568761E29DE7Q35656802-37D31A15-DE35-453F-A6AE-02770AECBF36Q35833625-2A8FB7A7-485D-4657-8C45-6401F872AE28Q36931868-EEF02AB0-FB61-4734-BD2F-338F5F8210D3Q37138961-AA80036F-D1B5-429C-AF9A-AA98B2B3EA92Q37233599-C632B9CA-5C80-4B1D-95E3-52F8C4648953Q37344903-A77BB014-7309-4A61-A579-02764D0B22CEQ37395743-1C40BADA-570D-478B-8142-3FA0036E10E4Q37412897-A470CAF6-B267-4E61-9831-E69ED5CC33A1Q37737830-A93CDB5E-CEE3-4CE0-A363-233F0B1322C5Q38674677-CA925A74-A3C7-40BE-8EE3-1E233887F3A8Q42375183-85C6E35C-1335-472E-B62E-08C178018165Q42484970-CC3C87F8-6A3F-439A-AEA6-C103C0D06614Q42771112-52A40CB6-0E0F-45EE-9B35-FA865D00C756Q43081741-5B8CE5C8-1DE3-405E-A306-4838800BE659Q43182095-D15809AD-2660-4785-B38D-89AB0FFAF21AQ43468988-CE41C2DE-6E26-4349-BE17-B6DFABB1C980Q46275241-9A629C00-6F25-4DF7-8EAF-61EAD96578BCQ46438011-0EDF3033-9DFE-4BA3-95D6-E537F06AE1DDQ46991200-91F2966F-6A95-456F-9C5D-C66F207B5C07Q53471537-C819AF41-63EE-4D07-AF93-5FD40F8A1C52
P2860
CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@ast
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@en
type
label
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@ast
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@en
prefLabel
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@ast
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@en
P2093
P2860
P1476
CD40 ligand promotes Mac-1 exp ...... rmation after vascular injury.
@en
P2093
Elena V Galkina
Guohong Li
Ian J Sarembock
James W Chumley
John M Sanders
Melissa H Bevard
P2860
P304
P356
10.2353/AJPATH.2008.070633
P407
P577
2008-03-18T00:00:00Z